CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating activities:
Net loss	$ (146,938)	$ (142,803)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2,228	2,547
Amortization of right-of-use operating lease assets	2,587	2,465
Amortization of other assets	582	639
Amortization of discount on investments, net	(7,108)	(9,257)
Amortization of debt issuance costs	1,642	1,667
Non-cash royalty revenue related to sale of royalties	(12,891)	(6,623)
Non-cash interest related to sale of future royalties	18,670	17,806
Stock-based compensation expense	29,718	31,340
Loss (gain) on investments	1,849	(2,332)
Non-cash losses related to other assets	61	133
Changes in operating assets and liabilities:
Contracts receivable	52,481	92,638
Inventories	1,010	499
Other current and long-term assets	(12,366)	11,048
Accounts payable	92	59
Income taxes	(25,968)	(13,869)
Accrued compensation	(43,039)	(46,190)
Accrued liabilities and other current liabilities	333	(42,887)
Deferred contract revenue	(13,718)	(46,818)
Net cash used in operating activities	(150,775)	(149,938)
Investing activities:
Purchases of short-term investments	(311,068)	(519,001)
Proceeds from sale of short-term investments	494,755	600,836
Purchases of property, plant and equipment	(12,577)	(4,493)
Acquisition of licenses and other assets, net	(651)	(1,237)
Net cash provided by investing activities	170,459	76,105
Financing activities:
Proceeds from issuance of common stock through equity plans, net	2,241	23,609
Principal payments on mortgage debt	(42)	(39)
Net cash provided by financing activities	2,199	23,570
Effects of exchange rates on cash	232	(114)
Net increase (decrease) in cash and cash equivalents	22,115	(50,377)
Cash and cash equivalents at beginning of period	242,077	399,266
Cash and cash equivalents at end of period	264,192	348,889
Supplemental disclosures of cash flow information:
Interest paid	92	95
Income taxes paid (refunds received)	(400)	13
Supplemental disclosures of non-cash investing and financing activities:
Amounts accrued for capital and patent expenditures	$ 460	$ 924